These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 36711490)

  • 1. ERBB4-mediated signaling is a mediator of resistance to BTK and PI3K inhibitors in B cell lymphoid neoplasms.
    Arribas AJ; Napoli S; Cascione L; Barnabei L; Sartori G; Cannas E; Gaudio E; Tarantelli C; Mensah AA; Spriano F; Zucchetto A; Rossi FM; Rinaldi A; de Moura MC; Jovic S; Pittau RB; Stathis A; Stussi G; Gattei V; Brown JR; Esteller M; Zucca E; Rossi D; Bertoni F
    bioRxiv; 2023 Jan; ():. PubMed ID: 36711490
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ERBB4-Mediated Signaling Is a Mediator of Resistance to PI3K and BTK Inhibitors in B-cell Lymphoid Neoplasms.
    Arribas AJ; Napoli S; Cascione L; Barnabei L; Sartori G; Cannas E; Gaudio E; Tarantelli C; Mensah AA; Spriano F; Zucchetto A; Rossi FM; Rinaldi A; Castro de Moura M; Jovic S; Bordone Pittau R; Stathis A; Stussi G; Gattei V; Brown JR; Esteller M; Zucca E; Rossi D; Bertoni F
    Mol Cancer Ther; 2024 Mar; 23(3):368-380. PubMed ID: 38052765
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resistance to PI3Kδ inhibitors in marginal zone lymphoma can be reverted by targeting the IL-6/PDGFRA axis.
    Arribas AJ; Napoli S; Cascione L; Sartori G; Barnabei L; Gaudio E; Tarantelli C; Mensah AA; Spriano F; Zucchetto A; Rossi FM; Rinaldi A; Castro de Moura M; Jovic S; Bordone-Pittau R; Di Veroli A; Stathis A; Cruciani G; Stussi G; Gattei V; Brown JR; Esteller M; Zucca E; Rossi D; Bertoni F
    Haematologica; 2022 Nov; 107(11):2685-2697. PubMed ID: 35484662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting IRAK4 with Emavusertib in Lymphoma Models with Secondary Resistance to PI3K and BTK Inhibitors.
    Guidetti F; Arribas AJ; Sartori G; Spriano F; Barnabei L; Tarantelli C; Von Roemeling R; Martinez E; Zucca E; Bertoni F
    J Clin Med; 2023 Jan; 12(2):. PubMed ID: 36675328
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PI3Kδ inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3Kδ and BTK inhibitors.
    Yahiaoui A; Meadows SA; Sorensen RA; Cui ZH; Keegan KS; Brockett R; Chen G; Quéva C; Li L; Tannheimer SL
    PLoS One; 2017; 12(2):e0171221. PubMed ID: 28178345
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma.
    Chiron D; Di Liberto M; Martin P; Huang X; Sharman J; Blecua P; Mathew S; Vijay P; Eng K; Ali S; Johnson A; Chang B; Ely S; Elemento O; Mason CE; Leonard JP; Chen-Kiang S
    Cancer Discov; 2014 Sep; 4(9):1022-35. PubMed ID: 25082755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PI3Kδ activation, IL6 over-expression, and CD37 loss cause resistance to the targeting of CD37-positive lymphomas with the antibody-drug conjugate naratuximab emtansine.
    Arribas AJ; Gaudio E; Napoli S; Yvon Herbaux CJ; Tarantelli C; Bordone RP; Cascione L; Munz N; Aresu L; Sgrignani J; Rinaldi A; Kwee I; Rossi D; Cavalli A; Zucca E; Stussi G; Stathis A; Sloss C; Davids MS; Bertoni F
    bioRxiv; 2023 Nov; ():. PubMed ID: 38014209
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting pathogenic mechanisms in marginal zone lymphoma: from concepts and beyond.
    Lue JK; O'Connor OA; Bertoni F
    Ann Lymphoma; 2020 Sep; 4():7. PubMed ID: 34667996
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Zanubrutinib in lymphoproliferative disorders: a comprehensive review.
    Muñoz J; Wang Y; Jain P; Wang M
    Ther Adv Hematol; 2022; 13():20406207221093980. PubMed ID: 35651781
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cotargeting of BTK and MALT1 overcomes resistance to BTK inhibitors in mantle cell lymphoma.
    Jiang VC; Liu Y; Lian J; Huang S; Jordan A; Cai Q; Lin R; Yan F; McIntosh J; Li Y; Che Y; Chen Z; Vargas J; Badillo M; Bigcal JN; Lee HH; Wang W; Yao Y; Nie L; Flowers CR; Wang M
    J Clin Invest; 2023 Feb; 133(3):. PubMed ID: 36719376
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resistance to BTK inhibition by ibrutinib can be overcome by preventing FOXO3a nuclear export and PI3K/AKT activation in B-cell lymphoid malignancies.
    Kapoor I; Li Y; Sharma A; Zhu H; Bodo J; Xu W; Hsi ED; Hill BT; Almasan A
    Cell Death Dis; 2019 Dec; 10(12):924. PubMed ID: 31801949
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Receptor tyrosine kinase ERBB4 mediates acquired resistance to ERBB2 inhibitors in breast cancer cells.
    Canfield K; Li J; Wilkins OM; Morrison MM; Ung M; Wells W; Williams CR; Liby KT; Vullhorst D; Buonanno A; Hu H; Schiff R; Cook RS; Kurokawa M
    Cell Cycle; 2015; 14(4):648-55. PubMed ID: 25590338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overcoming Acquired Epigenetic Resistance to BTK Inhibitors.
    Shaffer AL; Phelan JD; Wang JQ; Huang D; Wright GW; Kasbekar M; Choi J; Young RM; Webster DE; Yang Y; Zhao H; Yu X; Xu W; Roulland S; Ceribelli M; Zhang X; Wilson KM; Chen L; McKnight C; Klumpp-Thomas C; Thomas CJ; Häupl B; Oellerich T; Rae Z; Kelly MC; Ahn IE; Sun C; Gaglione EM; Wilson WH; Wiestner A; Staudt LM
    Blood Cancer Discov; 2021 Nov; 2(6):630-647. PubMed ID: 34778802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SAF-248, a novel PI3Kδ-selective inhibitor, potently suppresses the growth of diffuse large B-cell lymphoma.
    Zhang X; Duan YT; Wang Y; Zhao XD; Sun YM; Lin DZ; Chen Y; Wang YX; Zhou ZW; Liu YX; Jiang LH; Geng MY; Ding J; Meng LH
    Acta Pharmacol Sin; 2022 Jan; 43(1):209-219. PubMed ID: 33782541
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bruton's Tyrosine Kinase Inhibitors Prevent Therapeutic Escape in Breast Cancer Cells.
    Wang X; Wong J; Sevinsky CJ; Kokabee L; Khan F; Sun Y; Conklin DS
    Mol Cancer Ther; 2016 Sep; 15(9):2198-208. PubMed ID: 27256378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The HCK/BTK inhibitor KIN-8194 is active in MYD88-driven lymphomas and overcomes mutated BTKCys481 ibrutinib resistance.
    Yang G; Wang J; Tan L; Munshi M; Liu X; Kofides A; Chen JG; Tsakmaklis N; Demos MG; Guerrera ML; Xu L; Hunter ZR; Che J; Patterson CJ; Meid K; Castillo JJ; Munshi NC; Anderson KC; Cameron M; Buhrlage SJ; Gray NS; Treon SP
    Blood; 2021 Nov; 138(20):1966-1979. PubMed ID: 34132782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergistic Targeting of the Regulatory and Catalytic Subunits of PI3Kδ in Mature B-cell Malignancies.
    Cooney JD; Lin AP; Jiang D; Wang L; Suhasini AN; Myers J; Qiu Z; Wölfler A; Sill H; Aguiar RCT
    Clin Cancer Res; 2018 Mar; 24(5):1103-1113. PubMed ID: 29246942
    [No Abstract]   [Full Text] [Related]  

  • 18. Dual BTK/SYK inhibition with CG-806 (luxeptinib) disrupts B-cell receptor and Bcl-2 signaling networks in mantle cell lymphoma.
    Thieme E; Liu T; Bruss N; Roleder C; Lam V; Wang X; Nechiporuk T; Shouse G; Danilova OV; Bottomly D; McWeeney SK; Tyner JW; Kurtz SE; Danilov AV
    Cell Death Dis; 2022 Mar; 13(3):246. PubMed ID: 35296646
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New Treatment Options for Newly-Diagnosed and Relapsed Chronic Lymphocytic Leukemia.
    Iskierka-Jażdżewska E; Obracaj A; Urbaniak M; Robak T
    Curr Treat Options Oncol; 2022 Jun; 23(6):775-795. PubMed ID: 35357653
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BCL-2 Inhibition as Treatment for Chronic Lymphocytic Leukemia.
    Perini GF; Feres CCP; Teixeira LLC; Hamerschlak N
    Curr Treat Options Oncol; 2021 Jun; 22(8):66. PubMed ID: 34110507
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.